Keros Therapeutics, Inc. (KROS) insider trading.
In Q3 2026, insiders at Keros Therapeutics, Inc. reported 7 non-derivative transactions on 9 Forms 3, 4 and 5: 2 open-market purchases worth $21K and 4 sales worth $101K.
- Transactions
- 7
- Purchases (P)
- 2
- Sales (S)
- 4
- Net shares, P minus S
- -7,828
- Insiders
- 6
- Last filed
- 2026-08-20
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Bienaime Jean Jacques | Director | 2 | 2 | 0 |
| Newton Charles W. | Director | 1 | 0 | 1 |
| Lerner Lorena Raquel | Officer · Chief Scientific Officer | 1 | 0 | 1 |
| Cho Esther | Officer · Chief Legal Officer | 1 | 0 | 1 |
| Tanini Annita | Officer · Corp. Controller & VP, Finance | 1 | 0 | 1 |
| Prener Anne | Director | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-18 | Newton Charles W. | S (D) | 551 | $10.3 | 12,114 | Form 4 |
| 2026-08-18 | Lerner Lorena Raquel | S (D) | 3,568 | $10.29 | 27,559 | Form 4 |
| 2026-08-18 | Cho Esther | S (D) | 4,485 | $10.29 | 35,770 | Form 4 |
| 2026-08-18 | Tanini Annita | S (D) | 1,224 | $10.29 | 45,144 | Form 4 |
| 2026-08-17 | Bienaime Jean Jacques | P (A) | 1,000 | $10.27 | 19,592 | Form 4 |
| 2026-07-15 | Bienaime Jean Jacques | P (A) | 1,000 | $10.61 | 18,592 | Form 4 |
| 2026-07-01 | Prener Anne | A (A) | 13,786 | $0 | 13,786 | Form 4 |
Transaction codes in this quarter
Get KROS insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1664710&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · KROS company page · Keros Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Keros Therapeutics, Inc. (KROS)?
In Q3 2026, insiders at Keros Therapeutics, Inc. reported 7 non-derivative transactions on 9 Forms 3, 4 and 5: 2 open-market purchases worth $21K and 4 sales worth $101K. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Keros Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/kros.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.